Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera
about
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsIn vivo mechanisms of vaccine-induced protection against HPV infection.Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membraneNaturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccineMultiscale simulation of microbe structure and dynamics.Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.A review of clinical trials of human papillomavirus prophylactic vaccines.A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5Specificity of L1 peptides versus virus-like particles for detection of human papillomavirus-positive cervical lesions in females attending Engativa Hospital, Bogota, ColombiaAmino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants.HPV16 integration probably contributes to cervical oncogenesis through interrupting tumor suppressor genes and inducing chromosome instability.The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.Understanding and learning from the success of prophylactic human papillomavirus vaccines.Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer.Development of a human papillomavirus competitive luminex immunoassay for 9 HPV typesHuman papillomavirus major capsid protein L1 remains associated with the incoming viral genome throughout the entry process.The use of human papillomavirus seroepidemiology to inform vaccine policy.
P2860
Q27013018-F4390DFB-CF4D-4F36-8E18-28FD5BF2657EQ34125906-CD7FAB57-5C50-4C5D-B45C-21358B014C49Q35079915-7EB5AAB5-7452-458B-B62B-A74AD99FA13AQ35624920-34A9BAC2-BD73-4C63-BB6A-7BF110FE1145Q35861286-B75E34D2-1F2D-4CD6-B28B-FB10A111F7FFQ35947703-344B6F2E-39BA-4314-82BA-1578768A380FQ36017795-00919A70-45F0-4878-AAFB-B9494C6E71F6Q36058098-BA45E209-565F-491F-998C-BC59CAF059A2Q36088309-F9182FE2-7B71-4D06-8760-7B05351B3AD9Q36259403-075618BE-68AB-4035-BB39-D7379D94CC0AQ36448778-74D1C649-F18D-447A-A1F5-0A908FC60BD2Q36957928-F2358E58-38CB-4DB0-A6F0-B55FC2B9ABE1Q37162220-8B012A5C-7804-49E5-8046-1237E72CCD53Q37202927-2004AA10-9278-49D6-B485-031EBD8155A1Q37440587-49CFA3EC-D126-494A-B894-432DCF00F8EAQ37526148-42E17578-6F2D-4BF9-8BF1-5B66F3296A31Q37671423-3A2BA303-02DB-4946-9351-BAF4F17A1FDFQ38041983-49855ACE-33A4-4F5A-B19F-32D49CDA2256Q38182714-D957ACE7-FEA7-4DAA-BA40-69E0A53E3BA1Q38271441-EB998FD6-1EA7-4DAD-BC1C-A239B90DE2C7Q38752656-5615CF0B-2D55-4FAF-8D9D-B36FDC5A865DQ43013653-18BEE294-CFAF-4476-8160-B834293C951A
P2860
Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Identification of human papill ...... r neutralization by human sera
@ast
Identification of human papill ...... r neutralization by human sera
@en
Identification of human papill ...... r neutralization by human sera
@nl
type
label
Identification of human papill ...... r neutralization by human sera
@ast
Identification of human papill ...... r neutralization by human sera
@en
Identification of human papill ...... r neutralization by human sera
@nl
prefLabel
Identification of human papill ...... r neutralization by human sera
@ast
Identification of human papill ...... r neutralization by human sera
@en
Identification of human papill ...... r neutralization by human sera
@nl
P2093
P2860
P1433
P1476
Identification of human papill ...... r neutralization by human sera
@en
P2093
Denise A Galloway
Greg C Wipf
Joseph J Carter
Laura A Koutsky
Margaret M Madeleine
Stephen M Schwartz
P2860
P304
P356
10.1128/JVI.80.10.4664-4672.2006
P407
P577
2006-05-01T00:00:00Z